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Cancer cachexia is an important cause of death in cancer
patients (Warren, 1932), and in addition patients with
cachexia display a reduced response to chemotherapy (van
Eys, 1982). Cachexia is charaterised by progressive weight
loss, and catabolism of host body compartments, particularly
muscle and adipose tissue, is observed. It has been suggested
(Studley, 1936) that 30% loss of body weight is invariably
fatal, so attempts have been made to counter the weight loss
in cancer patients by administering total parenteral nutrition
(TPN). However, clinical studies giving extra calories via
TPN have failed to alter the weight loss, and in at least two
of the randomised TPN trials, a decreased survival was seen
in the TPN treatment arm (Chlebowski, 1985). Since weight
loss is one of the most common adverse systemic effects of
malignancy occurring early in the course of the disease (De
Wys, 1985), an understanding of the mechanism of cachexia
could obviously benefit a large number of patients.
In addition to possibly increasing the quality of life and
extending the length of survival of cancer patients, an under-
standing of the systemic effects of the tumour may provide a
locus for therapeutic intervention in the treatment of solid
tumours, if the products of catabolism of host tissues are
important in the maintenance of tumour growth.
The principal products released from the degradative activ-
ity on adipose tissue and muscle will be free fatty acids
(FFA) and amino acids. Tumours have a poor capacity to
synthesise their own lipids despite the fact that they are
important components of cellular membranes and also play
an important role as intracellular mediators such as eicos-
anoids, diacylglycerol and inositol phospholipids. Nutritional
conditions which lead to catabolism of host adipose tissue,
such as an acute fast (Sauer & Dauchy, 1987a) and acute
streptozotocin-induced diabetes (Sauer & Dauchy, 1987b),
result in a stimulation of tumour growth, suggesting that the
products from host fat stores may be limiting for tumour
growth in vivo. It is most likely that the mitogenic effect
results from the release ofpolyunsaturated fatty acids such as
linoleic or arachidonic acids. Phospholipids containing such
polyunsaturated fatty acids, esterfied to the sn-2 position of
the glycerol moiety, have been shown to stimulate cell growth
(Imagawa et al., 1989), possibly by inhibiting a guanosine
triphosphatase activating protein, which in turn inactivates
the ras protein (Tsai et al., 1989). This suggests that these
lipids can potentiate ras functions.
In addition amino acid requirements are altered in the
tumour-bearing state. Host leucine requirements have been
shown to be increased in the presence of a rapidly growing
murine tumour (Lazo, 1981), and depletion of the nonessen-
tial amino acid asparagine by the enzyme asparaginase has
led to the treatment of acute lymphocytic leukaemia in man
(Holland & Ohnuma, 1979). Some malignant cells have spe-
cific requirements for L-cysteine (Uren & Lazarus, 1979),
methionine (Tisdale, 1980), tyrosine and phenylalanine
(Demetrakopoulos & Brennan, 1982), serine and threonine
(Pizer & Reagan, 1972). Removal of one amino acid by the
tumour would lead to a depression of host protein synthesis,
since normal protein synthesis requires the full complement
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of amino acids. Disposal of the remaining amino acids has
been postulated to explain the abnormal gluconeogenesis
seen in cancer patients (Stein, 1978). In view of the extra
requirements of the tumour for specific nutrients, it is not
surprising that catabolism of host tissues is so common in
cancer.
Model systems of cachexia
In order to understand the underlying mechanisms of cancer
cachexia it is important that an appropriate model system is
used. Cachexia can appear in patients with tumours which
are less than 0.01% of the total body weight (Nathanson &
Hall, 1974), and the total tumour mass in the majority of
cancer patients rarely exceeds 0.5 Kg (Costa, 1977). Cachexia
is also not related to the growth rate or anatomical site of
involvement of the tumour. Few of the experimental models
which have been used to study the mechanisms of cachexia
fulfill the criteria that cachexia should be an early effect of
the tumour, and be present with a small tumour burden.
Instead cachexia is usually studied in rapidly growing rodent
tumours, and appears as a late effect, usually just before
death, when the tumour mass has reached a high proportion
of the total weight of the animal. Usually these models
attribute the cachexia to a drop in food intake and competi-
tion of the tumour with the host for essential nutrients
(Garattini et al., 1980). The few models which do fulfill the
criteria of an early effect and a small tumour mass, observe
weight loss without a detectable loss of appetite (Strain et al.,
1980; Bibby et al., 1987; Tanaka et al., 1990).
In view of the small tumour mass producing weight loss in
such models, it is unlikely that a simple competition between
host and tumour is responsible. Indeed, if the tumour-bear-
ing state is compared with pregnancy, the foetus grows at a
much faster rate, and is a higher proportion of the total body
weight than most tumours. However, in this case the mother
actually increases weight. It is also unlikely that weight loss
arises solely from an enhanced gluconeogenesis to supply the
glucose requirements of the tumour (Gold, 1974), although
futile cycles such as the Cori cycle and an increased lipo-
genesis from glucose probably contribute to the increased
metabolic demands in the tumour-bearing state.
Mechanism of cachexia
We have considered the hypothesis that wasting occurs
through direct catabolism of host components by tumour
products. There is a considerable amount of data in the
literature to support such a hypothesis, particularly with
regard to lipid mobilisation. Thus nonviable preparations of
Krebs-2 carcinoma cells, when injected into male Swiss mice,
were able to produce a decrease in carcass fat of a level
comparable with that obtained by viable cell preparations
(Costa & Holland, 1966). Using '4CO2 production from 14C
fatty acid labelled adipose tissue as a measure of lipolysis
Kitada et al. (1980) were able to show that extracts of a
thymic lymphoma, as well as serum from mice bearing such a
tumour, and culture medium from the cell line growing in
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vitro, were able to mobilise fatty acids from the hosts'
adipose tissue. The fact that activity was obtained with the in
vitro cell line suggested that the lipid mobilising factor was
tumour rather than host derived.
Carcass lipid depletion in tumour-bearing nude mice has
been shown to be a function of tumour type rather than
tumour burden (Hollander et al., 1986), suggesting that only
certain tumours are capable of elaborating lipid mobilising
factors. In animals bearing a transplantable colon adenocar-
cinoma (MAC16) weight loss was associated with an elevated
plasma lipid mobilising activity (Beck & Tisdale, 1987). Re-
lated colon adenocarcinomas which did not produce weight
loss had low levels of lipolytic activity, of the order of 10%
of that found in the MAC16 tumour. This suggests that the
mobilisation of host lipids may be a quantitative pheno-
monen, with all tumours having some capacity to produce
such catabolic factors, and explains why depletion of host
lipids is a function of tumour type rather than tumour
burden.
Mediators of cachexia
Considerable effort has been devoted to determining the
nature of the circulatory factor present in cachectic animals.
Early studies by Kitada et al. (1981) suggested that the lipid
mobilising factor produced by thymic lymphoma cells was a
heat stable protein of molecular weight of about 5 kDa, while
later studies reported the active material to be of much
higher molecular weight, and to be formed by aggregation of
the low molecular weight material (Kitada et al., 1982). A
somewhat similar acidic (pI4.7) lipid mobilising factor of
molecular weight 65 to 74 kDa (toxohormone L), has been
found in the pleural fluid from patients with malignant lym-
phoma and the ascites fluids of patients with ovarian car-
cinoma or hepatoma (Masuno et al., 1981).
Further characterisation of either of these materials has
not been reported, although proteolysis of toxohormone L to
low molecular weight materials did not destroy lipolytic
activity, suggesting some similarity to the low molecular
weight material investigated by Kitada et al. (1981).
Most recent studies have concentrated on a macrophage
product, cachectin, regarded as the mediator of cachexia in
animals infected with Trypanosomes (Rouzer & Cerami,
1980) and later shown to be homologous to tumour necrosis
factor (TNF) (Beutler et al., 1985a). Several studies have
demonstrated the ability of TNF to induce weight loss in
experimental animals (Oliff et al., 1987). Weight loss pro-
duced by TNF is typified by a marked anorexia, and the
decrease in food and water intake is directly proportional to
the decrease in body weight (Mahony et al., 1988). However,
anti-TNF antisera has been shown to delay, but not fully
protect against the decrease in food intake in sarcoma-
bearing mice (Sherry et al., 1989), suggesting that other
factors in addition to TNF may be responsible for the
anorexia in tumour-bearing animals. It has been suggested
that TNF produces an effect on lipid metabolism through an
inhibition of the enzyme lipoprotein lipase (Beutler et al.,
1985b), and thus depletion of host lipids would be mediated
through a different mechanism from the action of the direct
catabolic factors mentioned above. Inhibition of lipoprotein
lipase by TNF results in hypertriglyceridemia. However,
hypertriglyceridemia persists even with tachyphylaxis to the
anorectic effects of TNF, suggesting that the two are not
inevitably linked (Grunfeld et al., 1989).
Although there is a considerable amount of literature on
the biological effects of TNF, the role in cancer cachexia is
not clear. Attempts to reverse the cachexia in tumour-bearing animals with anti-TNF antibodies have produced equivocal results (Sherry et al., 1989). Unfortunately, both models used
by these workers had a higher tumour burden, and measure-
ments were made at the time of death. In sarcoma-bearing mice anti-TNF antibodies apparently reduced the loss of
both carcass and fat mass on the day of death. However, two
factors were not taken into consideration. Firstly, animals
given anti-TNF antibodies were eating more than control
animals when measurements were made, and secondly treat-
ment reduced tumour size, which would also be expected to
reduce catabolism of host tissues. In a second study with
Lewis lung adenocarcinoma-bearing mice, anti-TNF anti-
bodies diminished the degree of carcass lipid depletion and
prevented hypertriglyceridemia. However, as indicated above
(Grunfeld et al., 1989) hypertriglyceridemia may not be
linked to the anorexia/cachexia syndrome produced by TNF.
In neither model did anti-TNF antibodies affect the develop-
ment ofanaemia, hypoalbuminaemia or the increase in serum
myeloid P concentration seen with increasing tumour burden.
These results suggest that if TNF is involved in the weight
loss in some experimental models then other factors must
also be present to explain all of the features of cachexia.
Three lines of evidence are required to support the role of
a postulated cachectic factor in the development of cachexia.
(1) There should be measurable circulatory levels of the
factor and the appearance and level of the material should
be correlated with the degree of the cachexia in view of the
parabiotic transfer ofcachexia in rats (Norton et al., 1985).
(2) Injection of the factor into non weight-losing animals
should produce a syndrome similar to the cachectic situa-
tion.
(3) Inhibition of the action of the cachectic factor should
abolish the cachexia, and may also inhibit tumour growth
by deprivation of the tumour of essential nutrients.
Correspondence between circulatory levels ofcachecticfactors
and degree ofcachexia
Using tumour cells transfected with the human TNF gene, a
correlation has been established between weight loss, ano-
rexia and serum levels of TNF (Oliff et al., 1987). As the
authors point out, however, it may be necessary for TNF to
be continuously present in the animals circulation for clini-
cally significant changes in metabolic functions to be induced.
However, in another murine model of cachexia, the MAC16
adenocarcinoma, where profound cachexia occurs it has been
impossible to demonstrate elevated levels of TNF over that
found in other tumours which do not induced cachexia, even
in the presence of endotoxin (Mahony et al., 1988). Most
studies with cancer patients have also reported undetectable
serum levels of TNF (Selby et al., 1987), even in patients that
had lost eight to 40% of their pre-morbid weight (Socher et
al., 1988). Two studies have, however, reported elevated
serum levels of TNF, one in children with malignancy
(Saarinen et al., 1990), and another in cancer patients with
active disease (Balkwell et al., 1987), although in neither
study was the level of TNF related to the weight loss and the
latter study did not claim to have measured TNF but a
'TNF-like' activity. While the inability to detect TNF in the
plasma of cachectic patients may be attributed to the low
sensitivity of assays presently available (Beutler & Cerami,
1987), elevated levels of TNF have been detected in other
diseases where weight loss occurs, such as the acquired
immunodeficiency syndrome (AIDS) (Lahdevirta et al.,
1988).
This inability of TNF to be detectable in the serum of
cachectic animals/patients has led to the search for other
materials which may play a role in the human condition.
Using murine adipocytes in vitro as a bioassay to detect lipid
mobilising activity, we have been able to detect a rise in the
plasma level of lipolytic activity in animals bearing the
MAC16 adenocarcinoma only when weight loss occurred
(Groundwater et al., 1990). The rise in the plasma level of
lipolytic activity reached a maximum when the animals had
lost 16% of the body weight (Figure la), and thereafter
declined.
Occassionally animals bearing the MAC16 tumour do not
develop weight loss and for these animals there is no increase
in plasma lipid mobilising activity (Figure lb). Using the
same assay system the serum lipolytic activity was found to
be much higher in cancer patients with weight loss than a
group of patients with Alzheimer's disease and comparableCANCER CACHEXIA 339
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Figure 1 Changes in serum lipolytic activity (0) with weight
loss (0) in a, animals bearing the MAC16 tumour which lost
weight and in b, animals bearing the MAC16 tumour, but with-
out weight loss. Results are expressed as mean ± s.e.m. for four
animals per group. Lipolytic activity is expressed as j.moles
glycerol released per 105 adipocytes per ml plasma in a 2 h
incubation. The average value for non tumour-bearing controls
was 0.5±0.2pmoles glycerol 10 adipocytes-'ml-'.
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Figure 2 Relationship between serum lipolytic activity and
weight loss in a group of cancer patients. The lipolytic activity is
expressed as in Figure 1. The average value for normal subjects
was 0.06±0.01 jlmoles glycerol 105 adipocytes 'ml-'.
weight loss (Groundwater et al., 1990). As for animals bear-
ing the MAC16 tumour the serum level of lipolytic activity in
cachectic cancer patients was proportional to the degree of
weight loss when the total body weight loss did not exceed
20% (Figure 2). Patients who responded to therapy showed a
decrease in the plasma levels of lipid mobilising activity,
which correlated with the level of response (Beck et al.,
1990). The lipid mobilising activity was characterised by the
retention by DEAE cellulose, and using this criterion it was
observed that similar material was absent from normal
serum. This suggests that the lipid mobilising factor is acidic
in character, similar to that previously reported (Kitada et
al., 1981; Masuno et al., 1981), and is different from the
natural lipolytic hormones, which are all basic in character.
Effect ofcachecticfactors on host body weight
A number of studies have demonstrated the ability of TNF
to induce weight loss in experimental animals, although some
workers question the ability of TNF alone to yield a sus-
tained cachectic effect (Mullen et al., 1990). In all cases
weight loss is accompanied by a marked anorexia, and the
depression in food and water intake is probably responsible
for the wasting effect. Indeed when the anorexia is counter-
acted with the synthetic steroid megestrol acetate the ability
of TNF to induce weight loss is abolished (Beck & Tisdale,
1990). Megestrol acetate has been shown to produce weight
gain in more than 80% of cancer patients administered this
agent, with a subjective improvement of appetite occurring in
most cases (Aisner et al., 1988). Thus TNF may be responsi-
ble for the anorexia commonly encountered in cancer
cachexia. However, the cachectic effect of TNF when admin-
istered parenterally is usually transient, since tachyphylaxis
soon develops. In order to produce a prolonged weight loss
escalating doses of TNF are required, which exceed the LD50
of the agent (Tracey et al., 1988). Thus experimentally-
induced weight loss may be due to the toxic effect of TNF,
since a similar condition is observed with the antitumour
agent mitozolomide (Mahony & Tisdale, 1988). These results
suggest that other factors may be required to explain the
weight loss produced by TNF-producing tumours (Oliff et
al., 1987).
Treatment of animals with the lipid mobilising factor
isolated from the MAC16 tumour also produces a decrease in
body weight (Figure 3). This weight loss occurs without an
alteration in food intake, and is more pronounced in tumour-
bearing animals than in non tumour-bearing animals.
21
0)1
C,, 0H -2_
°' -4-a
cg-
-6 X, .
-c~~~~~~~~~~~~
-8- .O .O . . .
0 10 20 3 0 50
Time (hours)
Figure 3 Effect of a purified extract of culture medium from
MAC16 cells containing lipid mobilising activity on the body
weight of male NMRI mice (starting weight 25-30 g) bearing the
MAC16 tumour, but without weight loss. Animals were adminis-
tered I00fl1 of the purified factor (corresponding to 0.1 ymoles
glycerol released 105 adipocytes-' 2 h-') three times daily by i.p.
injection (O) and body weights were monitored three times per
day. a, P<0.05; b, P<0.01; c, P<0.005 from saline injected
controls (-) by Students t-test.
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Relationship between inhibition ofpostulated cachecticfactor
and cachexia
While there has been a large number of studies aimed at
determining the role of TNF in cachexia, interestingly very
few studies have attempted to reverse the cachexia by anti-
bodies to TNF. In the study of Sherry et al. (1989), anti-
TNF antibodies did significantly reduce the extent of carcass
protein and fat loss in a sarcoma model, as well as the
tumour wet and dry weights, but unfortunately measure-
ments were made on the day of death. In the other model
investigated, the Lewis lung adenocarcinoma animals did not
lose weight, although carcass lipid depletion was partially
reversed by anti-TNF antibodies. Until more studies have
been performed with other more relevant models of cachexia,
the potential use of anti-TNF therapy cannot be evaluated.
In vitro studies on the lipid mobilising factor elaborated by
the MAC16 tumour showed inhibition by both insulin and
3-hydroxy butyrate (Beck & Tisdale, 1987). Insulin is an
important anabolic hormone which has been suggested as a
possible supportive measure in the total nutritional manage-
ment of the cancer patient (Schein et al., 1979). In animals
bearing the MAC16 tumour daily insulin administration was
shown to reduce host body weight loss, and increase both
carcass fat and muscle mass, without an effect on food or
water consumption (Beck & Tisdale, 1989a). This was only
achieved, however, by an increase (about 50%) in the final
tumour weight. While in a rat model insulin was shown to
produce a significant increase in host body weight without
affecting tumour growth (Moley et al., 1985) the known
growth stimulatory properties of insulin (Barnes & Sato,
1980) should lead to caution if the use in the nutritional
management of cancer patients is being considered.
Medium chain triglycerides (MCT) are usually utilised to
induce ketosis in vivo, since they are transported directly via
the hepatic portal vein to the liver, where they are rapidly
oxidised to two carbon units by ,B-oxidation, and yield high
levels of ketone bodies (Cotter et al., 1987). When animals
bearing the MAC16 tumour were fed an isocaloric, isonitro-
genous diet in which the carbohydrate calories were replaced
by lipid in the form of MCT, with up to 80% of the energy
derived from MCT, weight loss was reduced by an amount
comparable with that obtaied by daily insulin administration,
but with a decrease in tumour weight (Tisdale et al., 1987).
The effect occurred without an alteration in caloric consump-
tion, and was associated with an increase in both the fat and
non-fat carcass mass, and both nitrogen balance and urea
excretion were restored to that in non tumour-bearing
animals (Beck & Tisdale, 1989b). Cancer patients with severe
weight loss (mean 32%) also showed an increase in body
weight when fed an isocaloric diet in which 70% of the
calories were derived from MCT (Fearon et al., 1988). How-
ever the effect appeared to occur without an alteration in
host nitrogen balance or whole-body protein synthesis or
turnover rates. These results suggest that inhibitors of the
lipid mobilising factor in vitro are also effective inhibitors of
cachexia in vivo, both in murine models and in cancer
patients.
Perhaps the most convincing data has come from recent
results which have shown that the most effective reversal of
weight loss in mice bearing the MAC16 tumour is achieved
when the carbohydrate component of the diet is replaced by
lipids derived from fish oil (Tisdale & Dhesi, 1990). In this
case weight loss is completely prevented when the fish oil
comprised 50% of the total calories and body composition
analysis showed that loss of both carcass fat and non-fat
mass was completely prevented. Again food intake in weight
gaining animals was not changed showing that weight rever-
sal was not due to an effect on energy intake. In this case
tumour growth rate was also significantly reduced,although
the effect of the fish oil diet on the cachexia exceeded the
effect on tumour growth rate, suggesting that the inhibition
of the cachexia produced a secondary effect on tumour
growth rate.
Fish oil is mainly composed of the essential fatty acids
eicospentaenoic (EPA) and docosahexaenoic (DHA) acids. In
vitro investigations on the individual components of the fish
oil showed that EPA was a selective inhibitor of the tumour
lipid mobilising factor and tumour-induced proteolysis (Tis- dale & Beck, 1991). The inhibitory effect was not seen with
DHA, or indeed any other fatty acid of either the (n-3) or
(n-6) series. In vivo only EPA was effective in inhibiting both
weight loss and catabolism of host lipids and proteins, and
DHA was totally ineffective. In addition, while in vitro
studies showed both EPA and DHA to be inhibitors of the
growth of the MAC16 tumour, only EPA was effective in
inhibiting tumour growth in vivo (Tisdale & Beck, 1991). This
suggests that the in vivo effect of this agent differs from the in
vitro effect, which is probably due to peroxide formation, and
since only EPA has anti-cachectic activity it probably can be
attributed to the inhibition of the cachexia.
This suggests that the catabolic effects of the tumour are
important in the supply of nutrients essential for tumour
growth. The antitumour effect of EPA in vivo appears to be
reversed by linoleic acid, suggesting that this fatty acid,
which is essential for tumour growth, may be supplied by the
breakdown of host lipids.
Mechanisms ofaction ofthe tumour lipidmobilisingfactor at
the cellular level
The catabolic action of most hormones is thought to be
mediated through an elevation of intracellular cyclic AMP.
In adipocytes this causes activation of protein kinase with the
subsequent activation of an inactive form of triglyceride lipase by phosphorylation. Like P-adrenergic stimuli and
ACTH the tumour lipid mobilising factor causes an elevation
in the intracellular level of cyclic AMP in adipocytes,
although unlike the former a prolonged stimulation ofcyclic AMP production is observed, in a similar manner to that
found with bacterial toxins (Sharp & Hynie, 1971). This
suggests that the tumour lipolytic factor may interact directly with guanine nucleotide-binding proteins (G-proteins) involv-
ed in signal transduction across plasma membranes.
Stimulation ofcyclic AMP levels in adipocytes by P-adren-
ergic stimuli, ACTH and the tumour lipid mobilising factor
are inhibited by EPA, suggesting that the effect is exerted
somewhere in the cyclase system. The exact molecular mech-
anism of action of EPA remains to be identified, but a
possible role in the action of G-proteins is shown by the
reduced level of ras p21 in mammary tumours from rats fed
a fish oil containing diet (Karmali et al., 1989).
Conclusion
Rapid wasting ofbody tissues leading to cachexia are charac- teristic features of a number of diseases, although it is
unlikely that there is a similar mediator of cachexia, in the
same way that it is simplistic to look for a common cure for
cancer. Cachexia is a typical feature of infectious diseases where the invading pathogen may lead to stimulation of the immune system and cytokine production. However, the cachexia of cancer is not normally associated with the pre-
sence ofinfection and while the outward symptoms may look similar, it is unlikely that a single mediator could explain the
heterogeneous pattern of changes seen in a wide spectrum of
diseases. This raises the possibility that other factors in addi-
tion, or instead of the known cytokines, may mediate the
changes seen in cancer cachexia. Further structural infor-
mation of these factors is required for a full understanding of
the condition.
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